

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 17, 2020

VistaGen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

NEVADA
(State or other jurisdiction of incorporation)

000-54014
(Commission File Number)

20-5093315
(IRS Employer Identification Number)

343 Allerton Ave.
South San Francisco, California 94090
(Address of principal executive offices)

(650) 577-3600
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	VTGN	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 17, 2020, VistaGen Therapeutics, Inc. (the “Company”) held its 2020 Virtual Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted upon at the Annual Meeting and the results of the voting are set forth below.

Proposal No. 1 – Election of Directors

	<u>For</u>	<u>Withheld</u>
Jon S. Saxe, J.D., LL.M.	14,242,885	7,608,782
Ann M. Cunningham, MBA	15,498,222	6,353,445
Jerry B. Gin, Ph.D., MBA	14,243,764	7,607,903
Shawn K. Singh, J.D.	15,387,738	6,463,929
H. Ralph Snodgrass, Ph.D.	15,518,454	6,333,213
Brian J. Underdown, Ph.D.	14,244,113	7,607,554

The Company’s Directors are elected by a plurality of the votes cast. Accordingly, each of the nominees named above was elected to serve on the Board of Directors until the 2021 Annual Meeting of Stockholders, or until her or his successor is elected and qualified.

Proposal No. 2 – Ratification of Appointment of Auditors

	<u>For</u>	<u>Against</u>	<u>Abstain</u>
Votes	34,045,984	6,434,176	142,139

The vote required to approve this proposal was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, stockholders ratified the appointment of OUM & Co. LLP as the Company’s independent auditors for the fiscal year ending March 31, 2021.

Item 7.01 Regulation FD Disclosure.

Following the adjournment of the formal portion of the Annual Meeting, Mr. Shawn Singh, the Company’s Chief Executive Officer, delivered closing remarks. A copy of Mr. Singh’s closing remarks is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

See Exhibit Index.

Disclaimer.

This Current Report on Form 8-K may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company’s plans, objectives, expectations and intentions; and (ii) other statements identified by words such as “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: September 18, 2020

By: /s/ Shawn K. Singh
Shawn K. Singh, JD
Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Closing Remarks made by Mr. Shawn Singh at the VistaGen Therapeutics, Inc. 2020 Annual Meeting of Stockholders, dated September 17, 2020



Nasdaq: VTGN

www.VistaGen.com



Looking beyond the standard of care for anxiety, depression and other CNS disorders

2020 Virtual Annual Meeting of Stockholders

Closing Remarks from Shawn K. Singh, JD, Chief Executive Officer and Director

Thank you to the stockholders who participated in this, our first, virtual annual meeting, as well as those who submitted their proxies prior to the meeting but were unable to participate.

I would like to bring attention to some alarming trends we see involving America's state of mind – trends relating to mental illness in America and medications in the current standard of care that we believe fall far short of a skyrocketing need.

Even before the onset of the COVID-19 pandemic and recent civil unrest, mental illness, especially anxiety and depression, had a vice-like grip on millions of Americas. Our mental health crisis was already taking a toll on families, employers and mental health professionals across the country. Pre-pandemic prevalence data on the mental illnesses on which our product candidates are focused – anxiety and depression - reveal alarming numbers: 40 million American adults suffering with anxiety, and over 17 million battling depression – before the pandemic.

While these historical numbers are alarming, the coronavirus pandemic and its diverse and far-reaching consequences involving many aspects of our lives – education of our children, employment, economic loss, health, safety, and social relationships - has greatly amplified the pre-pandemic trends.

And even as things have started to open up and important progress is being made with potential vaccines and antiviral drug solutions by our colleagues in the biotechnology and pharmaceutical industries, the lingering psychological impacts of the pandemic are starting to take shape in ways that suggest to us that we are in for a long-term mental health crisis well beyond the scope revealed by pre-pandemic data.

As has always been the case, psychotherapy will be critically important in the years ahead. Also, medications to complement effective psychotherapy will be critically important. Unfortunately, after now many decades of use by millions of patients and tens of millions of prescriptions by mental health professionals, we believe it is clear that the anti-anxiety and antidepressant medications that are part of the current standard of care for anxiety and depression disorders fall short of the needs of patients and caregivers.

For example, benzodiazepines, or benzos, widely-used for anxiety disorders are associated with significant side effects, such as sedation and cognitive and memory impairment, as well as serious risks of misuse, addiction and, especially when combined with opioids, death. Antidepressants, often prescribed for both anxiety and depression take a long time (weeks to months) to deliver therapeutic benefits, if they deliver any benefit at all, and they are also associated with considerable side effects and safety concerns.

So now more than ever, fundamentally different medications for anxiety and depression are needed, and such medications will be needed for many years to come in the aftermath of the COVID-19 pandemic.

Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen - PH94B, PH10 and AV-101 - are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders.

With the FDA's recent approval enabling us to replicate the design of the highly statistically significant (p=0.002) Phase 2 study of PH94B in Social Anxiety Disorder for our pivotal Phase 3 study of PH94B for the acute treatment of anxiety in adults with SAD, together with our new partnership for development and commercialization of PH94B for anxiety disorders in key markets in Asia, our receipt of a \$5M non-dilutive upfront payment from that partnering agreement, and our receipt of net proceeds of \$12.9 million from our public offering of common stock last month, we are more excited than ever about your company's future and our multiple opportunities to develop and commercialize innovative medications for anxiety and depression – medications we believe have the potential to go beyond the current standard of care and change lives.

Should you or anyone you know be in need of information about finding help for treatment of mental illness, please note that we have provided important contact information on the Finding Help page of our website at <https://www.vistagen.com/finding-help>.

On behalf of our entire team at VistaGen, thank you for your support; we wish you safety and good health.

Forward-Looking Statements

Various statements in this message are "forward-looking statements" concerning VistaGen's future expectations, plans and prospects, including the potential for successful Phase 3 development of PH94B for acute treatment of anxiety in adults with social anxiety disorder, as well as development of PH10 and AV-101 as potential treatments in multiple CNS indications. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that are discussed in the section entitled "Risk Factors" in our most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2020, and our subsequent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in the company's other filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.

VistaGen Therapeutics, Inc. / www.VistaGen.com / IR@VistaGen.com
